Bleichmar Fonti & Auld LLP announced on November 3, 2026 that a securities class action lawsuit, captioned Darcy v. The Chemours Company, No. 26-cv-1299, has been filed against The Chemours Company (NYSE:CC) and certain senior executives, alleging misrepresentation of demand for its Opteon refrigerant products.

Key Highlights

  • Stock drop: Chemours shares fell $3.34 per share, or 18.63%, on August 5, 2026, from a closing price of $17.93 to $14.59.
  • Alleged misrepresentation: The complaint alleges Chemours did not disclose that customers were already oversupplied with Opteon products heading into 2026.
  • Guidance cut: On August 4, 2026, Chemours reportedly cut its 2026 adjusted EBITDA guidance by approximately 11%, to $775M-$825M from $800M-$900M.
  • Lead plaintiff deadline: Investors have until December 7, 2026 to ask the court to be appointed lead plaintiff.
  • Court and case: The action is pending in the U.S. District Court for the District of Delaware, captioned Darcy v. The Chemours Company, No. 26-cv-1299.
  • Legal basis: Claims are asserted under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

Allegations and Background in the Chemours Opteon Class Action

According to the announcement by Bleichmar Fonti & Auld LLP, the class action centers on Chemours's Opteon line of refrigeration chemicals, which carry a reduced ozone-depletion footprint. The complaint alleges that Chemours represented "sustained double-digit" Opteon expansion would be "driven by the continued regulatory adoption" of the U.S. AIM Act, enacted by Congress in late 2020 to direct EPA oversight of the transition to alternative refrigerants. Chemours also reportedly provided 2026 net sales guidance of 3% to 5% growth and adjusted EBITDA guidance of $800M-$900M, citing "higher . . . demand" in its Opteon segment.

As alleged in the complaint, Chemours failed to disclose that customers were already oversupplied with Opteon products as a result of the AIM Act transition, creating what the complaint describes as an "oversupplied channel heading into 2026." The firm's announcement states that on August 4, 2026, Chemours reported Q2 2026 financial results showing an approximately 1% year-over-year decrease in net sales and disclosed that customers had "built additional inventory" of Opteon products the prior year and that aftermarket channels had been filled.

Following that announcement, Chemours's stock fell 18.63% on August 5, 2026, according to the filing. The lawsuit names The Chemours Company (NYSE:CC) and certain of its senior executives as defendants. The announcement notes that all representation is on a contingency fee basis and that shareholders are not responsible for court costs or litigation expenses, subject to court approval of any fees.

What Was Disclosed

Bleichmar Fonti & Auld LLP announced a securities class action against NYSE:CC and certain executives, alleging fraud related to Opteon demand disclosures. The case, No. 26-cv-1299, is pending in the U.S. District Court for the District of Delaware, with a lead plaintiff deadline of December 7, 2026.